Abstract
The molecular basis of many leukaemias is now known, allowing precise diagnosis. Treatment of chronic myeloid leukaemia is now possible by targeting of the BCR-ABL tyrosine kinase. The underlying molecular abnormalities in acute leukaemias allow the outlook for individual patients to be assessed at diagnosis and therapy tailored accordingly. Analysis of V(H) genes in B-cell malignant disorders allows these to be placed in the hierarchy of B-cell development and may provide prognostically valuable information.
MeSH terms
-
Acute Disease
-
Chromosome Aberrations / genetics*
-
Chromosome Disorders
-
Chronic Disease
-
Genetic Testing
-
Hodgkin Disease / diagnosis
-
Hodgkin Disease / genetics*
-
Hodgkin Disease / therapy
-
Humans
-
Karyotyping
-
Leukemia, Lymphoid / blood
-
Leukemia, Lymphoid / diagnosis
-
Leukemia, Lymphoid / genetics*
-
Leukemia, Lymphoid / therapy
-
Leukemia, Myeloid / blood
-
Leukemia, Myeloid / diagnosis
-
Leukemia, Myeloid / genetics*
-
Leukemia, Myeloid / therapy
-
Lymphoma, Non-Hodgkin / diagnosis
-
Lymphoma, Non-Hodgkin / genetics*
-
Lymphoma, Non-Hodgkin / therapy
-
Molecular Biology*
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / therapy
-
Prognosis